Trial Profile

Phase II clinical study of SJP 002C for COVID-2019 infections

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 25 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SJP-002C (Primary)
Indications COVID 2019 infections
Focus Adverse reactions

Most Recent Events

24 Jun 2024 According to a Sen Jam Pharmaceutical media release, with the anticipation of positive results, company plans to seek FDA approval to commence Phase 3 clinical trials.
24 Jun 2024 According to a Sen Jam Pharmaceutical media release, company announced completion of enrollment in this trial.
23 May 2024 Planned End Date changed to 1 Jul 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com